Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review.
Int J Chron Obstruct Pulmon DisSep 10, 2026 (epub)
Christopher E Brightling, Klaus F Rabe, Dave Singh et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the efficacy of biologics in patients with moderate to very severe COPD, focusing on randomized controlled trials. It found that no biologics reduced acute exacerbations of COPD (AECOPD) in the overall population without baseline blood eosinophil count (BEC) limits. However, reductions in AECOPD were observed in patients with a baseline BEC ≥300 cells/µL for certain biologics.
Key findings
- No biologics reduced AECOPD in patients without baseline BEC limits.
- Benralizumab, dupilumab, and mepolizumab reduced AECOPD in patients with BEC ≥300 cells/µL.
- Improvements in pre-bronchodilator FEV1 were noted for dupilumab and tezepelumab in patients with BEC ≥300 cells/µL.
- Astegolimab improved SGRQ-C total score in patients with BEC >170 cells/µL.
Why it matters
Understanding the efficacy of biologics in specific patient subgroups can guide clinicians in selecting appropriate treatments for COPD, particularly in those with elevated eosinophil counts, potentially improving patient outcomes.